(Q42682504)
Statements
Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain (English)
X Carbonell-Estrany
R Burgos-Pol
J Figueras-Aloy
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference